Cite
Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol. 2002;29(1):87-92doi: 10.1053/sonc.2002.30148.
Gordon, L. I., Witzig, T. E., Wiseman, G. A., Flinn, I. W., Spies, S. S., Silverman, D. H., Emmanuolides, C., Cripe, L., Saleh, M., Czuczman, M. S., Olejnik, T., White, C. A., & Grillo-López, A. J. (2002). Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in oncology, 29(1), 87-92. https://doi.org/10.1053/sonc.2002.30148
Gordon, Leo I, et al. "Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma." Seminars in oncology vol. 29,1 (2002): 87-92. doi: https://doi.org/10.1053/sonc.2002.30148
Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanuolides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-López AJ. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol. 2002 Feb;29(1):87-92. doi: 10.1053/sonc.2002.30148. PMID: 28140097.
Copy
Download .nbib